1,150 reports of this reaction
4.3% of all DARUNAVIR reports
#1 most reported adverse reaction
FOETAL EXPOSURE DURING PREGNANCY is the #1 most commonly reported adverse reaction for DARUNAVIR, manufactured by Janssen Products LP. There are 1,150 FDA adverse event reports linking DARUNAVIR to FOETAL EXPOSURE DURING PREGNANCY. This represents approximately 4.3% of all 26,718 adverse event reports for this drug.
Patients taking DARUNAVIR who experience foetal exposure during pregnancy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FOETAL EXPOSURE DURING PREGNANCY is moderately reported among DARUNAVIR users, representing a notable but not dominant share of adverse events.
In addition to foetal exposure during pregnancy, the following adverse reactions have been reported for DARUNAVIR:
The following drugs have also been linked to foetal exposure during pregnancy in FDA adverse event reports:
FOETAL EXPOSURE DURING PREGNANCY has been reported as an adverse event in 1,150 FDA reports for DARUNAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
FOETAL EXPOSURE DURING PREGNANCY accounts for approximately 4.3% of all adverse event reports for DARUNAVIR, making it one of the most commonly reported side effect.
If you experience foetal exposure during pregnancy while taking DARUNAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.